Results 171 to 180 of about 170,256 (261)

Cost‐Effectiveness Analysis of Transoral Robotic Surgery Versus Radiotherapy Alone for Early‐Stage HPV‐Associated Oropharynx Squamous Cell Carcinoma in Australia

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Introduction Transoral robotic surgery (TORS) and radiotherapy are both recognised as effective treatment options for early‐stage HPV‐associated oropharyngeal squamous cell carcinoma (HPV‐OPSCC). TORS offers the benefit of a shorter total treatment duration; however, a proportion of patients require adjuvant radiotherapy with or without ...
Lan Gao, June Corry, Danny Rischin, Tao Xing   +3 more
wiley   +1 more source

Sacituzumab-govitecan plus pembrolizumab: redefining first-line therapy in PD-L1-positive advanced triple-negative breast cancer. [PDF]

Transl Cancer Res
de Lima WAL, Gouveia MC, Bonadio RC.
europepmc   +1 more source

Impact of Metformin and Diabetes on Tumor Response to Total Neoadjuvant Therapy in Advanced Rectal Cancer: A Multicenter Retrospective Cohort Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In advanced rectal cancer patients receiving total neoadjuvant therapy (TNT), overall tumor response did not differ by diabetes status or metformin use. However, among diabetic patients, metformin use was associated with higher overall complete response rates. These findings suggest a potential benefit of metformin in enhancing TNT response in diabetic
Sergei Bedrikovetski, Mahima Raju, Tracy Fitzsimmons, Ishraq Murshed, Timothy J. Price, Michael Penniment, Sudarsha Selva‐Nayagam, Tarik Sammour   +7 more
wiley   +1 more source

Benchmarked Colorectal Cancer Outcomes in a Metropolitan Hospital: A 5‐Year Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In metastatic disease, patients with lung‐only metastasis had the best 5‐year survival at 46.0% and curative‐intent approaches can dramatically improve survival. ABSTRACT Introduction Colorectal cancer (CRC) remains a major contributor to cancer‐related mortality worldwide, with survival influenced by many prognostic factors.
Jialin Du, Vincent Wang, Basil D'Souza, Russell Hodgson   +3 more
wiley   +1 more source

Safety, Immunovirologic, and Central Nervous System Effects of PD-1 Inhibition in People With HIV Without Malignancy. [PDF]

J Infect Dis
Reoma LB, Johnson TP, Cheung K, Smith BR, Pérez L, Wiebold A, Migueles SA, Connors M, Boritz EA, Zahid M, Lai C, Gill J, Shah S, Lyndaker A, Burbelo PD, Maldarelli F, Lane HC, Shin J, Hammoud DA, Nair G, Nath A.   +20 more
europepmc   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, David Godbolt, Amy Ives, Kirsten Popplewell, Zarnie Lwin, Sally Pearson, Kimberley Nelson, Jason Madore, William C Dougall, Brett G. M. Hughes   +11 more
wiley   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

The efficacy and safety of pembrolizumab in the treatment of HER2-negative advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis of emerging clinical data. [PDF]

Front Immunol
Yang Y, Jiang L, Zhang G, Li K, Li D.
europepmc   +1 more source

Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
There is limited understanding of the impact of underlying RAS/RAF mutational status on total neoadjuvant therapy metastatic tumor response rates in curative Stage IV rectal cancer patients. Complete metastatic tumor response to TNT was demonstrated in half as many mRAS as wtRAS patients and disease progression was higher in patients harboring RAS ...
Tracy R. Fitzsimmons, Z. Bunjo, E. L. Neo, A. Badiei, M. Penniment, S. Selva‐Nayagam, A. Ruszkiewicz, J. Wong, T. Sammour   +8 more
wiley   +1 more source

Pembrolizumab-induced psoriasis and radiation recall: a shared immune pathway unveiled. [PDF]

An Bras Dermatol
Nougues M, Luna PC, Tirelli LL, Larralde M.   +3 more
europepmc   +1 more source